Androgen replacement in women: A commentary

被引:94
作者
Davis, S [1 ]
机构
[1] Jean Hailes Fdn, Clayton, Vic 3168, Australia
关键词
D O I
10.1210/jc.84.6.1886
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is increasing evidence to suggest that many postmenopausal women experience symptoms alleviated by androgen therapy and that such symptoms may be secondary to androgen deficiency. Affected women complain of fatigue, low libido, and diminished well-being, symptoms easily and frequently attributed to psychosocial and environmental factors. When such symptoms occur in the setting of low circulating bioavailable testosterone, testosterone replacement results in significant improvement in symptomatology and, hence, quality of life for the majority of women. Whether the apparent therapeutic effects of testosterone replacement are mediated by testosterone and its metabolite 5 alpha- dihydrotestosterone or are a consequence of aromatization to estrogen is not known. Despite the paucity of data regarding its effects, inclusion of testosterone in postmenopausal hormone replacement regimens is not uncommon and is likely to become more widespread with the availability of preparations developed specifically for women. Other novel and even more controversial potential indications for androgen therapy in women are currently being evaluated. These include use in women with premature ovarian failure, premenopausal androgen deficiency symptoms, postmenopausal and glucocorticosteroid-related bone loss, alleviation of wasting syndrome secondary to human immunodeficiency virus infection, and management of premenstrual syndrome, The aim of this commentary is to very briefly review the rationale for the use of testosterone in women, create awareness of some of the therapeutic options available in various countries, and stimulate discussion of this important aspect of women's health.
引用
收藏
页码:1886 / 1891
页数:6
相关论文
共 50 条
  • [1] REACTION OF METHANESULFONYL NITRENE WITH BENZENE - ATTEMPTS TO GENERATE SULFONYL NITRENES FROM SOURCES OTHER THAN AZIDES
    ABRAMOVITCH, RA
    BAILEY, TD
    TAKAYA, T
    UMA, V
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1974, 39 (03) : 340 - 345
  • [2] Bone loss in young women with karyotypically normal spontaneous premature ovarian failure
    Anasti, JN
    Kalantaridou, SN
    Kimzey, LM
    Defensor, RA
    Nelson, LM
    [J]. OBSTETRICS AND GYNECOLOGY, 1998, 91 (01) : 12 - 15
  • [3] *AUST MEN SOC COUN, 1999, IN PRESS CONS AUSTRA
  • [4] SEXUALITY IN SEXAGENARIAN WOMEN
    BACHMANN, GA
    LEIBLUM, SR
    [J]. MATURITAS, 1991, 13 (01) : 43 - 50
  • [5] MEDROXYPROGESTERONE ACETATE THERAPY IN ADVANCED BREAST-CANCER - THE PREDICTIVE VALUE OF ANDROGEN RECEPTOR EXPRESSION
    BIRRELL, SN
    RODER, DM
    HORSFALL, DJ
    BENTEL, JM
    TILLEY, WD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) : 1572 - 1577
  • [6] Estradiol and testosterone in specific regions of the human female brain in different endocrine states
    Bixo, M
    Backstrom, T
    Winblad, B
    Andersson, A
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 55 (3-4) : 297 - 303
  • [7] Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls
    Bloch, M
    Schmidt, PJ
    Su, TP
    Tobin, MB
    Rubinow, DR
    [J]. BIOLOGICAL PSYCHIATRY, 1998, 43 (12) : 897 - 903
  • [8] Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis
    Booij, A
    Biewengabooij, CM
    HuberBruning, O
    Cornelis, C
    Jacobs, JWG
    Bijlsma, JWJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1996, 55 (11) : 811 - 815
  • [9] BRYAN RM, 1984, CANCER, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO
  • [10] 2-H